Wo_老虎社区_美港股上老虎

ZY95
2021-02-17

Europe Clinches Pfizer-BioNTech Deal for 200 Million More Doses

The European Union finalized an agreement with Pfizer Inc. and BioNTech SE for 200 million more dose

Europe Clinches Pfizer-BioNTech Deal for 200 Million More Doses

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":385258847,"tweetId":"385258847","gmtCreate":1613557541289,"gmtModify":1634553173462,"author":{"id":3575879813755575,"idStr":"3575879813755575","authorId":3575879813755575,"authorIdStr":"3575879813755575","name":"ZY95","avatar":"https://static.tigerbbs.com/3b057a08c7bda4c5308522a6721fe295","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Wo</p></body></html>","htmlText":"<html><head></head><body><p>Wo</p></body></html>","text":"Wo","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/385258847","repostId":1171944463,"repostType":4,"repost":{"id":"1171944463","kind":"news","pubTimestamp":1613553025,"share":"https://www.laohu8.com/m/news/1171944463?lang=&edition=full","pubTime":"2021-02-17 17:10","market":"us","language":"en","title":"Europe Clinches Pfizer-BioNTech Deal for 200 Million More Doses","url":"https://stock-news.laohu8.com/highlight/detail?id=1171944463","media":"Bloomberg","summary":"The European Union finalized an agreement with Pfizer Inc. and BioNTech SE for 200 million more dose","content":"<p>The&nbsp;European Union&nbsp;finalized an agreement with&nbsp;Pfizer Inc.&nbsp;and&nbsp;BioNTech SE&nbsp;for 200 million more doses of their Covid-19 vaccine, locking in a second-quarter supply boost as countries struggle to speed up their immunization drives.</p>\n<p>This second order significantly increases the number of doses available from the two companies for the bloc’s 27 member states. The contract includes a firm order for 200 million shots, with an option to request an additional 100 million, which could double the EU’s overall supply from the companies.</p>\n<p>As many as 75 million doses from the order will be shipped in the second quarter, European Commission President Ursula von der Leyen said when the deal was first&nbsp;announced&nbsp;in January.</p>\n<p>EU countries are far behind the U.S. and U.K. in the race to vaccinate as many people as possible, even as faster-spreading variants of the virus gain a stronger&nbsp;foothold&nbsp;on the continent.</p>\n<p>The commission is also seeking to boost its stock of vaccines from&nbsp;Moderna Inc., which, like Pfizer-BioNTech, has a shot based on messenger RNA technology. Unlike more conventional vaccines, the mRNA shots can be modified within weeks if necessary to protect against mutant versions of the virus.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Europe Clinches Pfizer-BioNTech Deal for 200 Million More Doses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEurope Clinches Pfizer-BioNTech Deal for 200 Million More Doses\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-17 17:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-02-17/europe-clinches-pfizer-biontech-deal-for-200-million-more-doses?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The European Union finalized an agreement with Pfizer Inc. and BioNTech SE for 200 million more doses of their Covid-19 vaccine, locking in a second-quarter supply boost as countries struggle to speed...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-02-17/europe-clinches-pfizer-biontech-deal-for-200-million-more-doses?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-02-17/europe-clinches-pfizer-biontech-deal-for-200-million-more-doses?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171944463","content_text":"The European Union finalized an agreement with Pfizer Inc. and BioNTech SE for 200 million more doses of their Covid-19 vaccine, locking in a second-quarter supply boost as countries struggle to speed up their immunization drives.\nThis second order significantly increases the number of doses available from the two companies for the bloc’s 27 member states. The contract includes a firm order for 200 million shots, with an option to request an additional 100 million, which could double the EU’s overall supply from the companies.\nAs many as 75 million doses from the order will be shipped in the second quarter, European Commission President Ursula von der Leyen said when the deal was first announced in January.\nEU countries are far behind the U.S. and U.K. in the race to vaccinate as many people as possible, even as faster-spreading variants of the virus gain a stronger foothold on the continent.\nThe commission is also seeking to boost its stock of vaccines from Moderna Inc., which, like Pfizer-BioNTech, has a shot based on messenger RNA technology. Unlike more conventional vaccines, the mRNA shots can be modified within weeks if necessary to protect against mutant versions of the virus.","news_type":1},"isVote":1,"tweetType":1,"viewCount":72,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}